 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SL-172154 / Shattuck
Trial completion date: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - Oct 3, 2024
P1, N=86, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Trial completion date: Apr 2025 --> Nov 2024
- || SL-172154 / Shattuck
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Oct 2, 2024
P1, N=160, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Trial completion date: Apr 2025 --> Nov 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
- || SL-172154 / Shattuck
Trial primary completion date: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - Aug 5, 2024
P1, N=86, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024 Trial primary completion date: Jul 2024 --> Dec 2024
- || SL-172154 / Shattuck
Enrollment closed: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - May 30, 2024
P1, N=86, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Trial primary completion date: Jul 2024 --> Dec 2024 Enrolling by invitation --> Active, not recruiting
- || SL-172154 / Shattuck
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Mar 26, 2024
P1, N=160, Recruiting, Sponsor: Shattuck Labs, Inc.
Enrolling by invitation --> Active, not recruiting N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
- || SL-172154 / Shattuck
Trial completion date, Trial primary completion date, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Dec 31, 2023
P1, N=107, Recruiting, Sponsor: Shattuck Labs, Inc.
- || SL-172154 / Shattuck
Enrollment status, Phase classification: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - Nov 29, 2023
P1, N=102, Enrolling by invitation, Sponsor: Shattuck Labs, Inc.
N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025 Recruiting --> Enrolling by invitation | Phase classification: P1b --> P1
- | SL-172154 / Shattuck
Phase classification, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Nov 21, 2023
P1, N=107, Recruiting, Sponsor: Shattuck Labs, Inc.
Recruiting --> Enrolling by invitation | Phase classification: P1b --> P1 Phase classification: P1a/1b --> P1
- SL-172154 / Shattuck
Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Ri... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5713;
Preliminary efficacy signals were detected in UnTx TP53m-MDS and R/R AML. A response to SL-172154 monotherapy, dose-dependent increases in serum cytokines and accumulation of mature myeloid cells in BM suggest a potential role for CD40 stimulation.
- || SL-172154 / Shattuck
Trial completion, Trial completion date: Phase 1 Study of SL-172154 (SIRP?-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov) - May 18, 2023
P1, N=34, Completed, Sponsor: Shattuck Labs, Inc.
A response to SL-172154 monotherapy, dose-dependent increases in serum cytokines and accumulation of mature myeloid cells in BM suggest a potential role for CD40 stimulation. Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2023
- SL-172154 / Shattuck
Phase 1 dose escalation study of SL-172154 (SIRP?-Fc-CD40L) in platinum-resistant ovarian cancer. (On Demand | Hall A; Poster Bd # 239) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2184;
P1
IRRs were readily manageable. Maximal CD47 and CD40 target engagement and CD40-dependent PD effects were observed with ?3mg/kg SL-172154.
- || SL-172154 / Shattuck
Enrollment closed, Trial completion date, Trial primary completion date: Phase 1 Study of SL-172154 (SIRP?-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov) - Nov 3, 2022
P1, N=34, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Maximal CD47 and CD40 target engagement and CD40-dependent PD effects were observed with ?3mg/kg SL-172154. Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
- ||| SL-172154 / Shattuck
Enrollment open: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - Sep 1, 2022
P1b, N=102, Recruiting, Sponsor: Shattuck Labs, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- ||| SL-172154 / Shattuck
New P1 trial: SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov) - Aug 2, 2022
P1b, N=102, Not yet recruiting, Sponsor: Shattuck Labs, Inc.
- SL-172154 / Shattuck
Enrollment change, Trial termination: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (clinicaltrials.gov) - May 25, 2022
P1, N=5, Terminated, Sponsor: Shattuck Labs, Inc.
Not yet recruiting --> Recruiting N=18 --> 5 | Active, not recruiting --> Terminated; Sponsor decision
- ||| SL-172154 / Shattuck
Enrollment open, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Apr 20, 2022
P1a/1b, N=107, Recruiting, Sponsor: Shattuck Labs, Inc.
N=18 --> 5 | Active, not recruiting --> Terminated; Sponsor decision Not yet recruiting --> Recruiting
- || SL-172154 / Shattuck
Enrollment closed: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (clinicaltrials.gov) - Mar 17, 2022
P1, N=18, Active, not recruiting, Sponsor: Shattuck Labs, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| SL-172154 / Shattuck
New P1 trial, Combination therapy: SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov) - Mar 10, 2022
P1a/1b, N=107, Not yet recruiting, Sponsor: Shattuck Labs, Inc.
- SL-172154 IV / Shattuck
Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPĪ±-Fc-CD40L) in subjects with platinum-resistant ovarian cancer (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_414;
P1
Dose escalation is ongoing. Trial Registration NCT04406623
- || SL-172154 / Shattuck
Enrollment open: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (clinicaltrials.gov) - Mar 21, 2021
P1, N=18, Recruiting, Sponsor: Shattuck Labs, Inc.
Trial Registration NCT04406623 Not yet recruiting --> Recruiting
- SL-172154 / Shattuck
[VIRTUAL] CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity () - Aug 31, 2020 - Abstract #PEGS2020PEGS_295;
CD47/SIRPa blockade enhances macrophage-mediated phagocytosis of tumor cells that are dying, or have been tagged with an ADCP-competent antibody, however this event does not enhance anti-tumor immunity in the absence of antigen presentation to CD8+ T cells. SIRPa-Fc-CD40L (SL-172154) links these two mechanisms via a Type I interferon response, and has shown profound activity in both mouse and non-human primate studies.
- || SL-172154 / Shattuck
New P1 trial: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (clinicaltrials.gov) - Aug 6, 2020
P1, N=18, Not yet recruiting, Sponsor: Shattuck Labs, Inc.
- || SL-172154 / Shattuck
Enrollment open: Phase 1 Study of SL-172154 (SIRP?-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov) - Jul 13, 2020
P1, N=33, Recruiting, Sponsor: Shattuck Labs, Inc.
SIRPa-Fc-CD40L (SL-172154) links these two mechanisms via a Type I interferon response, and has shown profound activity in both mouse and non-human primate studies. Not yet recruiting --> Recruiting
- || SL-172154 / Shattuck
New P1 trial: Phase 1 Study of SL-172154 (SIRP?-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov) - May 27, 2020
P1, N=33, Not yet recruiting, Sponsor: Shattuck Labs, Inc.